PDF(Pubmed)
Abstract：
OBJECTIVE: Data on the population-based epidemiology of hyperhidrosis (HH) are scarce. This study investigated the epidemiology and healthcare of HH in Germany.
METHODS: Claims data of adult persons insured by a German statutory health insurance (DAK-Gesundheit) between 2016 and 2020 were analysed. Included were persons aged 18 years and older with a diagnosis of HH (confirmed inpatient or outpatient diagnosis in the observation year) who were continuously insured. Following outcomes were measured: prevalence and incidence rates, severity of hyperhidrosis and inpatient and outpatient care by a group of specialists.
RESULTS: In 2020, 0.70% of insured adults were confirmed to have HH (mean age 59.5 years, SD 18.9, 61.6% female), with 9.24% having a \'localised\' form, 8.65% a \'generalised\' form and 84.80% an \'unspecified\' form. 0.04% of the total population had a severe form. The incidence was 0.35%. Localised HH was more common in younger age groups (18 to <30 years), while older age groups (70 to <80 years) were significantly more likely to suffer from generalised HH. Systemic anticholinergics were used in 4.55%, and botulinum toxin injection therapy in 0.81%. General practitioners were most frequently involved in care. Inpatient stays due to HH were very rare, with 0.14% in 2019 and 0.04% in 2020.
CONCLUSIONS: Multisource data analysis connecting primary and secondary data will be needed for a complete picture of the healthcare and epidemiology of HH.
METHODS: Claims data of adult persons insured by a German statutory health insurance (DAK-Gesundheit) between 2016 and 2020 were analysed. Included were persons aged 18 years and older with a diagnosis of HH (confirmed inpatient or outpatient diagnosis in the observation year) who were continuously insured. Following outcomes were measured: prevalence and incidence rates, severity of hyperhidrosis and inpatient and outpatient care by a group of specialists.
RESULTS: In 2020, 0.70% of insured adults were confirmed to have HH (mean age 59.5 years, SD 18.9, 61.6% female), with 9.24% having a \'localised\' form, 8.65% a \'generalised\' form and 84.80% an \'unspecified\' form. 0.04% of the total population had a severe form. The incidence was 0.35%. Localised HH was more common in younger age groups (18 to <30 years), while older age groups (70 to <80 years) were significantly more likely to suffer from generalised HH. Systemic anticholinergics were used in 4.55%, and botulinum toxin injection therapy in 0.81%. General practitioners were most frequently involved in care. Inpatient stays due to HH were very rare, with 0.14% in 2019 and 0.04% in 2020.
CONCLUSIONS: Multisource data analysis connecting primary and secondary data will be needed for a complete picture of the healthcare and epidemiology of HH.
摘要：
目的：基于人群的多汗症（HH）流行病学数据很少。这项研究调查了德国HH的流行病学和医疗保健。
方法：分析了2016年至2020年德国法定健康保险（DAK-Gesundheit）保险的成年人的索赔数据。包括18岁及以上诊断为HH（在观察年确认住院或门诊诊断）的持续参保人员。测量以下结果：患病率和发病率，多汗症的严重程度以及一组专家的住院和门诊护理。
结果：在2020年，0.70％的参保成年人被确认患有HH（平均年龄59.5岁，SD18.9，61.6%女性），9.24%的人有“本地化”表单，8.65%的“通用”表单和84.80%的“未指定”表单。总人口的0.04％具有严重形式。发病率为0.35%。局部HH在年轻年龄组(18至<30岁)更常见，而年龄较大的人群（70至<80岁）更有可能患广泛性HH。全身抗胆碱能药物的使用率为4.55％，和肉毒杆菌毒素注射治疗在0.81%。全科医生最常参与护理。因HH住院非常罕见，2019年为0.14%，2020年为0.04%。
结论：要全面了解HH的医疗保健和流行病学，需要进行连接主要和次要数据的多源数据分析。
方法：分析了2016年至2020年德国法定健康保险（DAK-Gesundheit）保险的成年人的索赔数据。包括18岁及以上诊断为HH（在观察年确认住院或门诊诊断）的持续参保人员。测量以下结果：患病率和发病率，多汗症的严重程度以及一组专家的住院和门诊护理。
结果：在2020年，0.70％的参保成年人被确认患有HH（平均年龄59.5岁，SD18.9，61.6%女性），9.24%的人有“本地化”表单，8.65%的“通用”表单和84.80%的“未指定”表单。总人口的0.04％具有严重形式。发病率为0.35%。局部HH在年轻年龄组(18至<30岁)更常见，而年龄较大的人群（70至<80岁）更有可能患广泛性HH。全身抗胆碱能药物的使用率为4.55％，和肉毒杆菌毒素注射治疗在0.81%。全科医生最常参与护理。因HH住院非常罕见，2019年为0.14%，2020年为0.04%。
结论：要全面了解HH的医疗保健和流行病学，需要进行连接主要和次要数据的多源数据分析。
